Clinical trial
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With…
NCT00080301 · R-Pharm, Industry · Completed
Key facts
| NCT number | NCT00080301 |
|---|---|
| Title | Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer |
| Official title | A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant |
| Lead sponsor | R-Pharm, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastases |
| Intervention type | Drug |
| Interventions | Ixabepilone + Capecitabine, Capecitabine |
| Enrollment | 752 |
| Start date | Sep 1, 2003 |
| Primary completion | Nov 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Mar 30, 2004 |
| Last update posted | Nov 2, 2020 |
| Countries | Argentina, Belgium, Brazil, Canada, China, France, Germany, Greece, Hungary, Italy, Malaysia, Mexico and 10 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: